Skip to main content
Join the Patient Engagement Forum.Share your experiences by joining our Patient Engagement Forum.

Physiological intracytoplasmic sperm injection (PICSI)

For most patients, having a routine cycle of proven fertility treatment is effective without using any treatment add-ons.

Our ratings indicate whether the evidence from studies shows that a treatment add-on is effective at improving treatment outcomes for someone undergoing fertility treatment. Our ratings do not tell you how much that treatment add-on improves your chances of having a baby – please discuss this with your clinic.

What is PICSI?

Physiological intracytoplasmic sperm injection (PICSI) is a technique used to select sperm to use in Intracytoplasmic sperm injection (ICSI) treatment. It involves placing sperm with hyaluronic acid (HA), a natural compound found in the body. PICSI identifies sperm that can bind to HA and these sperm are selected for use in treatment.

Ratings for PICSI
Rated black for increasing the chances of having a baby for patients having ICSI due to male factor infertility
Black traffic light
On balance, the findings from moderate/high quality evidence shows that this add-on has no effect on improving the chances of having a baby for patients having ICSI due to male factor infertility.
Rated black for older women having ICSI for male factor infertility
Black traffic light
On balance, the findings from moderate/high quality evidence shows that this add-on has no effect on improving the chances of having a baby for older women having ICSI for male factor infertility.
Rated grey for reducing the chances of miscarriage for women over the age of 35, having ICSI for male factor infertility
Grey traffic light
We cannot rate the effectiveness of this add-on at for reducing the chances of having a miscarriage for women over the age of 35 having ICSI for male factor infertility, as there is insufficient moderate/high quality evidence.

What do the ratings mean?

There are five ratings that indicate whether a treatment add-on is effective at improving treatment outcomes for someone undergoing fertility treatment, according to the evidence from studies. To make it easier to understand the scientific evidence for each treatment add-on we have a range of symbols and colours for each rated add-on below.

Green traffic light

On balance, findings from high quality evidence shows this add-on is effective at improving the treatment outcome.

Yellow traffic light

On balance, it is not clear whether this add-on is effective at improving the treatment outcome. This is because there is conflicting moderate/high quality evidence – in some studies the add-on has been found to be effective, but in other studies it has not.

Grey traffic light

We cannot rate the effectiveness of this add-on at improving the treatment outcome as there is insufficient moderate/high quality evidence.

Black traffic light

On balance, the findings from moderate/high quality evidence shows that this add-on has no effect on the treatment outcome.

Red traffic light

There are potential safety concerns and/or, on balance, findings from moderate/high quality evidence shows that this add-on may reduce treatment effectiveness.

All treatment add-ons on our list will have a rating to indicate whether the evidence shows that the treatment add-on is effective at improving the chances of having a baby for most fertility patients. Some treatment add-ons on our list may also have additional ratings for specific treatment outcomes. For example, whether the evidence shows that the treatment add-on reduces miscarriage. There may also be further ratings for specific patient groups, for example whether the evidence shows that the treatment add-on is effective for those who are aged over 40. Please see the individual webpages for each treatment add-on for their ratings.

An agreement between the HFEA and other professional and patient bodies (the 19th October 2023 consensus statement) states that treatments that have no strong evidence of their safety and/or effectiveness should only be offered in a research setting. Patients should not be charged extra to take part in research, including clinical trials.

What’s the evidence for PICSI?

PICSI has only been studied in patients undergoing ICSI due to male factor infertility, and there is no benefit to having PICSI where treatment is not due to male factor infertility.

There have been several studies comparing PICSI with standard ICSI for patients undergoing ICSI for male factor infertility and one high quality large RCT was carried out which showed that using PICSI did not increase the chances of having a baby.

The results of this large RCT did suggest that PICSI may be beneficial in reducing the chance of miscarriage. However, it is important to keep in mind that this evidence was a secondary outcome, this means that the study was not designed to investigate the effect of PICSI on miscarriage rate, making these secondary results less reliable. For this reason, it is important to discuss your individual circumstances with your doctor.

At the July 2023 Scientific and Clinical Advances Advisory Committee (SCAAC) meeting the Committee evaluated the evidence base for PICSI. Minutes of this discussion and the evidence used to inform this discussion are available on the SCAAC webpage.

This Cochrane review has further information on the evidence for PICSI.

Is this treatment add-on safe?

PICSI is a non-invasive test performed on a semen sample as an additional step in the ICSI process. The risks associated with the use of ICSI also apply to PICSI.

If you have any questions about the safety and risks, your clinic will be able to discuss whether a treatment add-on would be safe for you to use considering your specific medical history and circumstances.

Find out more about ICSI

Studies reviewed for this treatment add-on

The SCAAC have reviewed the following studies for PICSI:

Parmegiani 2012 10.1016/j.fertnstert.2012.05.043
Worrilow 2013 10.1093/humrep/des417
Majumdar 2013 10.1007/s10815-013-0108-9
Mokanszki 2014 10.3109/19396368.2014.948102
Troya 2015 10.5935/1518-0557.20150015
Lohinova 2017 PMID: 29099693
Erberelli 2017 10.5935/1518-0557.20170002
Korosi 2017 PMID: 28724183
Avalos-Durán 2018 10.5935/1518-0557.20180027
Miller 2019 10.1016/S0140-6736(18)32989-1
Hasanen 2020 10.1007/s10815-020-01913-4
Novoselsky 2021 10.1111/andr.12982
Hozyen 2022 10.1007/s43032-021-00642-y
Romany 2014 10.1016/j.fertnstert.2014.09.001
Troya 2015 10.5935/1518-0557.20150015
Romany 2017 10.1007/s10815-016-0838-6
Ziarati 2018 10.1080/14647273.2018.1424354

What are treatment add-ons?

In vitro fertilisation (IVF) and intrauterine insemination (IUI) are established treatments that have been proven effective for most patients. Treatment add-ons are optional non-essential treatments that may be offered in addition to such proven fertility treatment. The HFEA provides information on add-ons that meet the following criteria:

  • Additional treatments (to the core treatment e.g. IVF or IUI), that are being offered to the general patient population in licensed fertility clinics in the UK,
  • Where there are published scientific studies which claim to demonstrate that the treatment add-on improves the chances of having a baby or other treatment outcomes rated by the HFEA; but
  • where evidence of effectiveness for the use of the treatment in a clinical setting is lacking or absent; and
  • where patients need unbiased information about the effectiveness and risks of this treatment.

It is important to keep in mind that for most patients, having a routine cycle of proven fertility treatment is effective without using any treatment add-ons. If you are paying directly for your own treatment, you may want to think about whether it might be more effective and/or affordable to pay for multiple routine proven treatment cycles, rather than spending large sums of money on a single treatment cycle with treatment add-ons that haven’t been proven to be effective at increasing the likelihood of you having a baby.

We aim to publish clear and reliable information about some of the treatment add-ons that don’t have enough evidence to show that they are effective at improving your chances of having a baby and other relevant treatment outcomes. This provides useful information to patients and allows them to question the use of add-ons

Review date: 19 October 2025